These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33976881)

  • 21. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
    Chuntova P; Hou Y; Naka R; Yamamichi A; Chen T; Goretsky Y; Hatae R; Nejo T; Kohanbash G; Mende AL; Montoya M; Downey KM; Diebold D; Skinner J; Liang HE; Schwer B; Okada H
    Neuro Oncol; 2022 Feb; 24(2):259-272. PubMed ID: 34347086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme.
    Sabahi M; Jabbari P; Alizadeh Haghighi M; Soltani S; Soudi S; Rahmani F; Rezaei N
    Med Hypotheses; 2020 Apr; 137():109559. PubMed ID: 31962251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
    Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
    J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
    Song Y; Liu Q; Zuo T; Wei G; Jiao S
    Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
    Durgin JS; Henderson F; Nasrallah MP; Mohan S; Wang S; Lacey SF; Melenhorst JJ; Desai AS; Lee JYK; Maus MV; June CH; Brem S; O'Connor RS; Binder Z; O'Rourke DM
    Front Oncol; 2021; 11():669071. PubMed ID: 34026647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
    Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
    Choi BD; Suryadevara CM; Gedeon PC; Herndon JE; Sanchez-Perez L; Bigner DD; Sampson JH
    J Clin Neurosci; 2014 Jan; 21(1):189-90. PubMed ID: 24054399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
    Chen W; Xian N; Lin S; Liao W; Chen M
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of the alpha
    Cobb DA; de Rossi J; Liu L; An E; Lee DW
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification.
    Yu Q; Zhang M; Chen Y; Chen X; Shi S; Sun K; Ye R; Zheng Y; Chen Y; Xu Y; Peng J
    Int J Nanomedicine; 2020; 15():483-495. PubMed ID: 32158206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
    Caruso HG; Tanaka R; Liang J; Ling X; Sabbagh A; Henry VK; Collier TL; Heimberger AB
    J Neurooncol; 2019 Dec; 145(3):429-439. PubMed ID: 31686330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
    Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L
    Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma.
    Swan SL; Mehta N; Ilich E; Shen SH; Wilkinson DS; Anderson AR; Segura T; Sanchez-Perez L; Sampson JH; Bellamkonda RV
    Front Immunol; 2023; 14():1085547. PubMed ID: 36817432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.